Biodexa Pharmaceuticals (BDRX) announced the results of its Type C meeting with the U.S. Food and Drug Administration, FDA, regarding the ...

Biodexa Pharm stock has been trading in the range of $2.78 - $74.00 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq ...

it received a Staff Determination letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Ma July 23, 2024 Biodexa Pharmaceuticals PLC Announces Closing of $5.0 ...

Biodexa Pharmaceuticals announced a successful Type C meeting with the FDA, which has cleared the way to finalize the Phase 3 protocol for its drug eRapa in treating familial adenomatous polyposis ...

May 15, 2024 Biodexa Pharmaceuticals PLC (Biodexa or the Company) Posting of Annual Report & Notice of AGM Total Voting Rights Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a... Registrational phase ...

February 10, 2025 Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a therapeutic alternative with the potential... ByInvesting ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...